Access cutting-edge systemic mastocytosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access systemic mastocytosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic mastocytosis treatment provided free
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier
Sponsor: Blueprint Medicines Corporation
Check if you qualify for this systemic mastocytosis clinical trial in New York, NY
If you're searching for systemic mastocytosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic mastocytosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.